High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*

Abstract

Treatment with high-dose antithrombin III may increase survival time up to 90 days in patients with severe sepsis and high risk of death. This benefit may even be stronger when concomitant heparin is avoided.

Uncovering Hypercoagulability in Sepsis Using ROTEM® Thromboelastometry: A Case Series

“…Closely interconnected with the immunologic and endothelial system, recent data have indicated a contributing role of the coagulation system in the development of microcirculatory dysfunction and multiple organ failure in patients with sepsis [1][2][3]. Accordingly, anticoagulatory and anti-inflammatory therapies could reduce the severity of organ failure [4][5][6] and improve mortality in patients with sepsis and a high risk of death [7].…”

Cellular Mechanisms of MOF During Severe Sepsis and Septic Shock

“…In addition, many studies have demonstrated that coagulation can further activate the inflammatory cascade, and visa versa, leading to a positive-feedback interaction (StearnsKurosawa et al, 2011;Jagneaux et al, 2004;Dhainaut et al, 2001). Novel treatments targeting thrombin activity during sepsis has been shown to decrease serum bilirubin concentrations and prevent liver dysfunction (Nitescu et al, 2007;Inthorn et al, 1997); however its overall role in reducing septic mortality is still unclear (Wiedermann et al, 2006).…”

Effect of High-Dose Intravenous Immunoglobulin Administration on the Levels of Interleukin-6 in Patients with Sepsis

“…A previous study reported that the administration of high-dose antithrombin III improved 90-day survival times in patients with sepsis and septic shock complicated by disseminated intravascular coagulation [1]. And use of antithrombin III led to decrease of IL-6 levels [11].…”

“…Immunoglobulins counteract the effects of specific microorganisms and toxins by triggering various mechanisms, such as the opsonization process, complement system, antibody-dependent cell-mediated cytotoxicity, and increasing the susceptibility of bacterial cell walls to antimicrobial agents [1][2][3]. Due to these attributes, immunoglobulins are frequently used as adjuvant therapy for infections.…”